Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hansoh Pharma to Start China Trials of Novel Endometriosis Therapy

publication date: Jul 6, 2023

Jiangsu Hansoh Pharma was approved to start China trials of HS-10518, a novel drug aimed at managing moderate to severe pain associated with endometriosis. HS-10518 is an orally active non-peptide gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids. Hansoh believes the candidate will offer improved dosing convenience and a better safety profile than existing treatments. One year ago, Hansoh acquired China rights to the drug from South Korea’s TiumBio for $170 million plus tiered royalties on net sales. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital